Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2022.2106972
Abstract: ABSTRACT Introduction Myasthenia gravis is characterized by fluctuating muscle weakness that improves with rest and worsens with effort or throughout the day. Areas Covered Efgartigimod is a human IgG1–derived Fc fragment modified at five residues… read more here.
Keywords: abdeg technology; myasthenia; myasthenia gravis; treatment ... See more keywords